UCB (UCB.BR) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for UCB, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track UCB.BR live on Mooboard →

This week1

  • Aug 10, 2026
    UCB(UCB.BR)Phase 2/3 readout
    rozanolixizumab · Phase 2 / Phase 3 · Generalized Myasthenia Gravis
    NCT06149559: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis. Primary completion 2026-08-10 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Next 30 days1

  • Aug 31, 2026
    UCB(UCB.BR)Phase 2/3 readout
    Staccato alprazolam · Phase 3 · Stereotypical Prolonged Seizures
    NCT05077904: A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures. Primary completion 2026-08-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

Later19

  • Nov 16, 2026
    UCB(UCB.BR)Phase 2/3 readout
    Zilucoplan · Phase 2 / Phase 3 · Generalized Myasthenia Gravis
    NCT06055959: A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis. Primary completion 2026-11-16 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 21, 2026
    UCB(UCB.BR)Phase 2/3 readout
    Bimekizumab · Phase 3 · Hidradenitis Suppurativa
    NCT06921850: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa. Primary completion 2026-12-21 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 9, 2027
    UCB(UCB.BR)Phase 2/3 readout
    bimekizumab · Phase 3 · Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis
    NCT06506916: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis. Primary completion 2027-03-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 6, 2027
    UCB(UCB.BR)Phase 2/3 readout
    Rozanolixizumab · Phase 3 · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
    NCT05063162: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD). Primary completion 2027-05-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 17, 2027
    UCB(UCB.BR)Phase 2/3 readout
    Galvokimig · Phase 2 · Atopic Dermatitis
    NCT07277660: A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis. Primary completion 2027-05-17 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 17, 2027
    UCB(UCB.BR)Phase 2/3 readout
    rozanolixizumab · Phase 3 · Generalized Myasthenia Gravis
    NCT06540144: An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis. Primary completion 2027-08-17 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Oct 26, 2027
    UCB(UCB.BR)Phase 2/3 readout
    Zilucoplan · Phase 3 · Generalized Myasthenia Gravis
    NCT06435312: An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis. Primary completion 2027-10-26 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Dec 27, 2027
    UCB(UCB.BR)Phase 2/3 readout
    Bimekizumab · Phase 3 · Palmoplantar Pustulosis
    NCT07219420: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis. Primary completion 2027-12-27 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 12, 2028
    UCB(UCB.BR)Phase 2/3 readout
    Bimekizumab · Phase 3 · Enthesitis-related Arthritis; Juvenile Psoriatic Arthritis
    NCT06668181: An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis. Primary completion 2028-04-12 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2028
    UCB(UCB.BR)Phase 2/3 readout
    DZP · Phase 3 · Systemic Lupus Erythematosus
    NCT06617325: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus. Primary completion 2028-05-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 21, 2028
    UCB(UCB.BR)Phase 2/3 readout
    bimekizumab · Phase 3 · Moderate to Severe Plaque Psoriasis
    NCT06425549: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis. Primary completion 2028-08-21 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 30, 2028
    UCB(UCB.BR)Phase 2/3 readout
    Staccato alprazolam · Phase 3 · Stereotypical Prolonged Seizures
    NCT05076617: A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures. Primary completion 2028-11-30 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Dec 1, 2028
    UCB(UCB.BR)Phase 2/3 readout
    Rozanolixizumab · Phase 3 · Ocular Myasthenia Gravis
    NCT07463521: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis. Primary completion 2028-12-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 28, 2029
    UCB(UCB.BR)Phase 2/3 readout
    Galvokimig · Phase 2 · Non-cystic Fibrosis Bronchiectasis
    NCT07720375: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis. Primary completion 2029-02-28 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 29, 2029
    UCB(UCB.BR)Phase 2/3 readout
    Galvokimig · Phase 2 · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
    NCT07725939: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis. Primary completion 2029-06-29 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 16, 2029
    UCB(UCB.BR)Phase 2/3 readout
    Brivaracetam Film-coated tablet · Phase 3 · Childhood Absence Epilepsy; Juvenile Absence Epilepsy
    NCT06315322: A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy. Primary completion 2029-11-16 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 8, 2030
    UCB(UCB.BR)Phase 2/3 readout
    Brivaracetam · Phase 3 · Epilepsy
    NCT04715646: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures. Primary completion 2030-07-08 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 7, 2030
    UCB(UCB.BR)Phase 2/3 readout
    Dapirolizumab pegol · Phase 3 · Systemic Lupus Erythematosus
    NCT04976322: A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus. Primary completion 2030-08-07 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Jan 23, 2031
    UCB(UCB.BR)Phase 2/3 readout
    Rozanolixizumab · Phase 3 · Ocular Myasthenia Gravis
    NCT07465289: A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis. Primary completion 2031-01-23 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

How UCB has moved — past-year price reactions

How binary is UCB.BR? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.2%
typical day (1Y)
2
±10% days
36.4%
annualized vol
255
trading days
Largest single-day moves
  • +15.6%2025-09-29no matched headline
  • -13.5%2026-07-30no matched headline
  • -7.9%2026-02-26no matched headline
  • +7.4%2026-01-06no matched headline
  • -6.4%2025-10-31no matched headline
  • -5.7%2026-06-15no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

UCB — active clinical pipeline

UCB's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

13 assets24 programsPh1 5Ph2 3Ph3 15· 1 post-marketing (Ph4)
AreasAutoimmuneImmunologyNeuroscienceRare / GeneticOther
BimekizumabAutoimmune · IL-17A/IL17F
Phase 1
Moderate to Severe Plaque Psoriasis
Phase 3
Axial SpondyloarthritisEnthesitis-related ArthritisHidradenitis Suppurativa (2)Moderate to Severe Plaque Psoriasis (2)Palmoplantar Pustulosis
RozanolixizumabAutoimmune · FcRn
Phase 3
Generalized Myasthenia Gravis (2)Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)Ocular Myasthenia Gravis (2)
ZilucoplanAutoimmune · C5
Phase 1
Autoimmune
Phase 3
Generalized Myasthenia Gravis (2)
BrivaracetamNeuroscience · SV2A
Phase 3
Epilepsy
Brivaracetam Film-coated tabletNeuroscience
Phase 3
Childhood Absence Epilepsy
Dapirolizumab pegolAutoimmune · CD40L
Phase 3
Systemic Lupus Erythematosus
DZPAutoimmune
Phase 3
Systemic Lupus Erythematosus
Staccato alprazolamNeuroscience
Phase 3
Stereotypical Prolonged Seizures (2)
zilucoplan (RA101495)Autoimmune · C5
Phase 3
Generalized Myasthenia Gravis
GalvokimigRare / Genetic
Phase 2
Atopic DermatitisChronic Obstructive Pulmonary Disease With Chronic BronchitisNon-cystic Fibrosis Bronchiectasis
Bimekizumab regimen 1 ivAutoimmune
Phase 1
Psoriatic Arthritis
UCB0107 (bepranemab)Other · MAPT
Phase 1
Progressive Supranuclear Palsy
UCB5285Other
Phase 1
Healthy volunteers

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.